{
    "clinical_study": {
        "@rank": "154543", 
        "arm_group": {
            "arm_group_label": "Dacarbazine, carmustine, neulasta", 
            "arm_group_type": "Experimental", 
            "description": "Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether dacarbazine and carmustine at the doses\n      and schedule used in this study will help to increase tumor shrinkage."
        }, 
        "brief_title": "Dacarbazine and Carmustine in Metastatic Melanoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma Metastatic", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "In this phase II trial, patients with stage IV melanoma will be treated with dacarbazine and\n      carmustine commonly used in this cancer, but given using a schedule that might theoretically\n      improve on this combination.  Patients on this study will be assessed in terms of toxicity,\n      response rate, median duration of response, median time to disease progression, and median\n      survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must have a histologically-proven diagnosis of metastatic malignant melanoma\n             which has progressed on at least one prior systemic therapy.\n\n          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 and\n             estimated survival of at least 3 months.\n\n          3. Patients must be felt to have recovered from effects of prior cancer therapy, such as\n             past expected leukocyte nadir for chemotherapy (> 2 weeks).\n\n          4. Absolute granulocyte count of at least 1500/mm3; hemoglobin of at least 9 gm/dl;\n             platelet count of at least 100,000/mm3;  bilirubin must be less than 1.5 mg/dl; ALT\n             and AST must be less than 3 times the upper limit of normal; creatinine must be less\n             than or equal to 1.8 mg/dl.\n\n          5. Women of childbearing potential must have a negative pregnancy test and adequate\n             precautions to prevent pregnancy during treatment must be taken.\n\n          6. Patient consent must be obtained prior to entrance onto study.\n\n          7. Patients must have no evidence of significant cardiovascular disease including\n             history of recent (< 6 months) myocardial infarction, uncompensated congestive heart\n             failure, uncontrolled angina or cerebrovascular accident.\n\n        Exclusion Criteria:\n\n          1. Evidence of significant cardiovascular disease including history of recent (< 6\n             months) myocardial infarction, uncompensated congestive heart failure, uncontrolled\n             angina, or cerebrovascular accident.\n\n          2. Prior history of psychiatric disorder that could be exacerbated by or which could\n             preclude completion of this therapy.\n\n          3. Pregnancy or lactation.\n\n          4. Prior chemotherapy with carmustine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692691", 
            "org_study_id": "12-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dacarbazine, carmustine, neulasta", 
                "description": "Dacarbazine IV - Day 1", 
                "intervention_name": "Dacarbazine", 
                "intervention_type": "Drug", 
                "other_name": "DTIC"
            }, 
            {
                "arm_group_label": "Dacarbazine, carmustine, neulasta", 
                "description": "Carmustine IV- Day 2", 
                "intervention_name": "Carmustine", 
                "intervention_type": "Drug", 
                "other_name": "BCNU"
            }, 
            {
                "arm_group_label": "Dacarbazine, carmustine, neulasta", 
                "description": "Neulasta SC - Day 3", 
                "intervention_name": "Neulasta", 
                "intervention_type": "Drug", 
                "other_name": "pegfilgrastim"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "Dacarbazine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Melanoma Metastatic", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "contact": {
                "email": "marci.pierog@ctca-hope.com", 
                "last_name": "Marci Pierog, RN", 
                "phone": "623-207-3818"
            }, 
            "facility": {
                "address": {
                    "city": "Goodyear", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85338"
                }, 
                "name": "Western Regional Medical Center"
            }, 
            "investigator": {
                "last_name": "Walter Quan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Sequenced Chemotherapy With Dacarbazine and Carmustine With Neulasta\u00ae Support in Previously Treated Metastatic Melanoma", 
        "overall_contact": {
            "email": "marci-pierog@ctca-hope.com", 
            "last_name": "Marci Pierog, RN", 
            "phone": "623-207-3818"
        }, 
        "overall_contact_backup": {
            "email": "india.hill@ctca-hope.com", 
            "last_name": "India L Hill", 
            "phone": "623-207-3392"
        }, 
        "overall_official": {
            "affiliation": "Western Regional Medical Center", 
            "last_name": "Walter Quan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression free survival of patients with Stage IV melanoma who have had disease progression on at least one prior systemic therapy", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692691"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Western Regional Medical Center", 
            "investigator_full_name": "Walter Quan Jr., MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "response rate", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "median duration of response", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "median survival of patients treated with combination.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Western Regional Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Western Regional Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}